Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.

Nat Immunol

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Published: September 2024

AI Article Synopsis

Article Abstract

Despite various public health strategies, malaria caused by Plasmodium falciparum parasites remains a major global health challenge that requires development of new interventions. Extended half-life human monoclonal antibodies targeting the P. falciparum circumsporozoite protein on sporozoites, the infective form of malaria parasites, prevent malaria in rodents and humans and have been advanced into clinical development. The protective epitopes on the circumsporozoite protein targeted by monoclonal antibodies have been defined. Cryogenic electron and multiphoton microscopy have enabled mechanistic structural and functional investigations of how antibodies bind to the circumsporozoite protein and neutralize sporozoites. Moreover, innovations in bioinformatics and antibody engineering have facilitated enhancement of antibody potency and durability. Here, we summarize the latest scientific advances in understanding how monoclonal antibodies to the circumsporozoite protein prevent malaria and highlight existing clinical data and future plans for how this emerging intervention can be used alone or alongside existing antimalarial interventions to control malaria across at-risk populations.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41590-024-01938-2DOI Listing

Publication Analysis

Top Keywords

monoclonal antibodies
16
circumsporozoite protein
16
antibodies circumsporozoite
8
prevent malaria
8
malaria
6
circumsporozoite
5
monoclonal
4
circumsporozoite proteins
4
proteins emerging
4
emerging tool
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!